We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+5.46%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.81B
AUM Growth
-$1.51B
(-35%)
Cap. Flow
-$960M
Cap. Flow
% of AUM
-34.09%
Top 10 Holdings %
Top 10 Hldgs %
78.26%
Holding
40
New
1
Increased
8
Reduced
18
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$69M |
| 2 |
Baxter International
BAX
|
+$36.8M |
| 3 |
Humana
HUM
|
+$20.3M |
| 4 |
Cigna
CI
|
+$15.1M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$3.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$220M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$142M |
| 3 |
GSK
GSK
|
+$91.5M |
| 4 |
PTC Therapeutics
PTCT
|
+$84.8M |
| 5 |
Viatris
VTRS
|
+$78.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.93% |
| 2 | Miscellaneous | 43.07% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AnaptysBio
ANAB
$1.61B
| $13.9M | 0.5% |
750,000
-500,000
| -40% | -$8.34M |
|
27
Theravance Biopharma
TBPH
$885M
| $8.93M | 0.32% |
1,000,000
| – | – |
|
28
10x Genomics
TXG
$9.74B
| $8.73M | 0.31% |
1,000,000
| – | – |
|
29
Inogen
INGN
$137M
| $6.95M | 0.25% |
975,000
-1,025,000
| -51% | -$9.67M |
|
30
Structure Therapeutics
GPCR
$2.59B
| $5.19M | 0.18% |
300,000
| – | – |
|
31
OraSure Technologies
OSUR
$243M
| $3.03M | 0.11% |
900,000
-3,350,000
| -79% | -$12.3M |
|
32
Genmab
GMAB
$21.2B
| $979K | 0.03% |
50,000
| – | – |
|
33
Alkermes
ALKS
$7.72B
| – | – |
-1,500,000
| Closed | -$43.1M |
|
|
34
GSK
GSK
$101B
| – | – |
-2,500,000
| Closed | -$91.5M |
|
35
Herbalife
HLF
$1.25B
| – | – |
-3,000,000
| Closed | -$20.1M |
|
|
36
Jazz Pharmaceuticals
JAZZ
$15.8B
| – | – |
-1,150,000
| Closed | -$142M |
|
|
37
Medtronic
MDT
$119B
| – | – |
-2,750,000
| Closed | -$220M |
|
38
Medpace
MEDP
$17.3B
| – | – |
-125,000
| Closed | -$41.5M |
|
|
MRUS
39
DELISTED
Merus
MRUS
| – | – |
-250,000
| Closed | -$10.5M |
|
|
BKDT
40
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
| – | – |
-250,000
| Closed | -$17.2M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Camber Capital Management held 40 positions worth $2.81B, down 35% from $4.32B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Camber Capital Management withdrew a net $960M in Q1 2025, closing 8 positions and reducing 18 holdings. Its most notable exit was Medtronic, an estimated $220M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 58% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Camber Capital Management added an estimated $69M to Zimmer Biomet.
- Camber Capital Management added most to Zimmer Biomet in Q1 2025, an estimated $69M increase.
- Camber Capital Management's biggest Q1 2025 reduction was PTC Therapeutics, cutting an estimated $84.8M.
- Camber Capital Management fully exited Medtronic in Q1 2025, selling an estimated $220M.
- Camber Capital Management's ten largest holdings make up 78% of its $2.81B portfolio in Q1 2025.
- Camber Capital Management opened 1 new position and closed 8 in Q1 2025.
- Camber Capital Management's portfolio value fell 35% quarter-over-quarter to $2.81B.
Based on Camber Capital Management's 13F filing for Q1 2025, filed 15 May 2025.